Daily Brief Podcast
We tackle the health topics no one else wants to touch 💉🧠
—from obesity and high blood pressure
—to emotional eating and medication resistance
—to cultural myths that keep people sick 🧬❌
My mission is to deliver evidence-based truth—
real doctors. hard truths. no coddling. 🎯
🎧 Subscribe now and share with someone who’s tired of watered-down wellness.
Let’s change lives with facts—not fluff.
Daily Brief Podcast
Ozempic Isn’t “Too New” — Here’s the 20-Year Truth
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Are GLP 1 medications like Ozempic and Mounjaro really “too new” to trust?
In this episode, I break down one of the most common fears patients bring into the clinic when discussing GLP 1 medications for weight loss and diabetes treatment.
We discuss:
• How long GLP 1 medications have actually been studied
• Why Ozempic, Mounjaro, Wegovy, and related medications are not experimental treatments
• The difference between internet fear and evidence based medicine
• What physicians look at when evaluating medication safety
• Which patients should not take GLP 1 medications
• Why patients often feel overwhelmed by conflicting health information online
I also explain the importance of physician patient allyship when navigating obesity treatment and why understanding the science behind these medications matters more than social media fear mongering.
If you have ever wondered whether Ozempic or Mounjaro are truly safe long term, this episode will help you understand what decades of clinical data actually show.
Questions for Dr. Takem and the team
💡 Start your journey today with Maryland Primary Care & Wellness
Book your consultation: https://www.maryland-primarycare.com/